Creo Medical Group PLC Director/PDMR Shareholding (1445A)
22 December 2017 - 8:24PM
UK Regulatory
TIDMCREO
RNS Number : 1445A
Creo Medical Group PLC
22 December 2017
Creo Medical Group plc
Director/PDMR Dealing
The Company announces that on 22 December 2017, Christopher
Hancock, Chief Technology Officer, transferred ordinary shares from
his personal holding to his self-invested personal pension (SIPP)
via the sale of 36,716 ordinary shares at a price of 69.5p per
share and the purchase of 36,664 ordinary shares at a price of
69.5p per share. Following these transactions, Mr Hancock's total
interest in ordinary shares is 4,880,098 ordinary shares.
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Chris Hancock
--- ------------------------- ---------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Technology Officer
--- ------------------------- ---------------------------------
b) Initial notification Initial
/Amendment
--- ------------------------- ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ------------------------------------------------------------
a) Name Creo Medical Group plc
--- ------------------------- ---------------------------------
b) LEI 213800H188ZDCWWXFA21
--- ------------------------- ---------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------
a) Description of
the financial Ordinary shares of GBP0.001
instrument, type each
of instrument
Identification GB00BZ1BLL44
code
--- ------------------------- ---------------------------------
b) Nature of the Transfer of ordinary shares
transaction to SIPP via sale and purchase
--- ------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------ ----------
Sale of shares
from personal
holding at
69.5p per share 36,716
------------------ ----------
Purchase by
SIPP at 69.5p
per share 36,664
------------------ ----------
--- ------------------------- ---------------------------------
d) Aggregated information
- Aggregated volume
- Price
Weighted average price of
69.5 pence per share
--- ------------------------- ---------------------------------
e) Date of the transaction 21 December 2017
--- ------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange
--- ------------------------- ---------------------------------
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume/Mark Brett Pollard
+44 (0)129 160 6005 Connelly (NOMAD) / Mo Noonan
Richard.Rees@creomedical.com Michael Johnson +44 (0)203 727
/ Russell Kerr 1000
(Sales) creo@fticonsulting.com
+44 (0)207 397
8900
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing safer, less-invasive and more cost-efficient
option of treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFVDFFLLFID
(END) Dow Jones Newswires
December 22, 2017 04:24 ET (09:24 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024